Blood
Articles in this Issue
Rare composite of Rosai-Dorfman-Destombes disease and nodular lymphocyte-predominant B-cell (Hodgkin) lymphoma
Epidemiology, clinical features, and molecular basis of <i>TTMV</i> :: <i>RARA</i> -driven acute promyelocytic leukemia
Abstract Integration of torque teno mini virus (TTMV) generating the TTMV::RARA (retinoic acid receptor α) fusion represents a newly recognized subtype of acute promyelocytic leuke...
HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins
Abstract Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare but life-threatening condition in which maternal alloantibodies, generated during pregnancy, target human...
Bispecific antibodies in action: the reality of engagement
In pursuit of FNAIT biomarkers: αVβ3 specificity falls short
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Abstract Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DL...
α-Ketoglutarate promotes amino acid depletion and suppresses B-cell lymphoma growth and development
Abstract Targeting metabolic dependencies and “starving” malignant cells have long been considered potential strategies to treat cancer. However, with rare exceptions, the implemen...
Starving lymphoma with α-KG supplementation
ReXPOsing a weakness in TP53-mutant MDS and AML
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Abstract With up to 10 years of follow-up, we report results from the final analysis of RESONATE- 2, a phase 3 study of first-line ibrutinib vs chlorambucil for the treatment of ch...
Epigenetic changes by EZH2 inhibition increase translocations in B cells with high AID activity or DNA repair deficiency
Abstract The enhancer of zeste homolog 2 (EZH2) histone methyltransferase inhibitors tazemetostat and valemetostat recently have received approval for clinical use in follicular ly...
A clinical guide to <i>TP53</i> mutations in myeloid neoplasms
Abstract TP53 mutations are found in 10% to 15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is...
Making sense of factor VIII’s breakdown
Factor IXa and factor X influence factor VIIIa stability and inactivation mechanisms in vitro and in vivo
Abstract Deficiency of factor VIII (FVIII) causes hemophilia A (HA), and excess FVIII function increases venous thromboembolic risk. The phenotypic consequences of aberrant FVIII f...
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in <i>TP53</i> -mutated myeloid malignancies
Abstract TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most aggressive and chemotherapy-refractory myeloid neoplasms, with a median ove...